-- 
Constellation, Lam Research, Ruby Tuesday, TPC Group: U.S. Equity Movers

-- B y   L u   W a n g   a n d   J e f f   K e a r n s
-- 
2011-04-07T20:21:24Z

-- http://www.bloomberg.com/news/2011-04-07/constellation-lam-research-tpc-group-u-s-equity-movers.html
Shares of the following companies
had unusual moves in U.S. trading. Stock symbols are in
parentheses and prices are as of 4 p.m. in New York.  Allscripts Healthcare Solutions Inc. (MDRX)   fell the
most in the Russell 1000 Index, sliding 6.8 percent $20.96. The
software maker was cut to “hold” from “buy” at Auriga USA
LLC.  Bed Bath & Beyond Inc. (BBBY)   gained 10 percent to
$54.55 for the biggest rally in the Standard and Poor’s 500
Index. The home furnishings retailer forecast annual earnings of
$3.38 to $3.53 a share. That compares with the average analyst
projection of $3.33, Bloomberg data show.  Buckle Inc. (BKE)   rose 9.9 percent to $44.55, the
highest price since 1992. The teen retailer reported March sales
at stores open at least one year increased 8.4 percent from a
year earlier. Analysts expected a decline of 1.2 percent.  Constellation Brands Inc. (STZ)   rose 6.9 percent to
$21.79 for the second-biggest gain in the  S&P 500 . The world’s
largest wine company said that, excluding some items, it expects
to earn at least $1.90 a share in fiscal 2012. That beat the
average estimate of $1.89 from analysts in a Bloomberg survey.        Costco Wholesale Corp. (COST)   rose 3.8 percent to
$77.82, the third-biggest increase in the S&P 500. The largest
U.S. warehouse-club chain reported total comparable sales rose
13 percent in March, beating the 7.4 percent estimate.  Immucor Inc. (BLUD)   climbed 4.7 percent, the most since
Jan. 7, to $20.92. The maker of products used to screen donated
blood reported third-quarter earnings of 32 cents a share,
beating the average analyst projection of 26 cents a share,
according to data compiled by Bloomberg.  Immunogen Inc. (IMGN)   advanced 27 percent, the most
since July 2003, to $11.80. The Waltham, Massachusetts-based
drugmaker said that patients treated with T-DM1, which consists
of the company’s DM1 cancer cell-killing agent, had a
significant improvement in “progression-free survival.”  Lam Research Corp. (LRCX)   had the second-biggest decline
in the Russell 1000 Index, dropping 5 percent to $53.52. The
maker of chip-manufacturing equipment may disappoint investors
when reporting earnings for the current quarter as demand slows,
Citigroup Inc. wrote in a note, in which it added the idea of
selling the shares its Top Picks Live! list.  KLA-Tencor Corp. (KLAC)  , another semiconductor-equipment
maker, declined 4.6 percent to $44.06 for the biggest retreat in
the S&P 500.  Movado Group Inc. (MOV)   climbed 12 percent to $16.81,
the highest price since October 2008. The watch and jewelry
maker reported fourth-quarter earnings that beat analysts’
estimates and said it will resume paying dividends.  Pier 1 Imports Inc. (PIR)   rose 11 percent to $11.65, the
highest price since April 2006. The home-furnishings retailer
reported fourth-quarter earnings of 48 cents a share, beating
the average analyst estimate by 1 cent.  Ruby Tuesday Inc. (RT)   slumped 18 percent, the most
since December 2008, to $10.92. The casual-dining chain cut its
2011 earnings forecast to a range of 74 cents to 82 cents a
share, from 76 cents to 87 cents a share. That’s below the
average analyst projection of 91 cents a share.  TPC Group Inc. (TPCG)   jumped 13 percent to $36.71, the
highest price since 2004. The maker of petrochemical-derived
products had its share-price estimate increased to $42 from $39
at Oppenheimer & Co.  WD-40 Co. (WDFC)   fell 6.3 percent, the most since Jan.
11, to $40.90. The San Diego-based maker of lubricants and hand
soap cut its 2011 earnings forecast to a range from $2.23 to
$2.35 a share, from $2.25 to $2.40 share. The average analyst
forecast was $2.31 a share, Bloomberg data show.  XenoPort Inc. (XNPT)   rallied 56 percent to $9.96 for the
biggest gain in the Russell 2000 Index. The drugmaker and
GlaxoSmithKline Plc (GSK LN) won U.S. approval for a new
treatment for restless legs syndrome after more than a year of
delays.  To contact the reporter on this story:
 Lu Wang  in  New York  at   lwang8@bloomberg.net .  To contact the editor responsible for this story:
Nick Baker at   nbaker7@bloomberg.net . 